Tactile Systems Technology Shares Rise 8.1% on Strong Volume
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: NASDAQ.COM
- Strong Price Performance: Tactile Systems Technology's shares rose 8.1% in the last trading session, closing at $30.28 with significantly higher-than-average trading volume, reflecting market optimism about its future performance.
- Business Growth Momentum: The company continues to show growth in its lymphedema and airway clearance business lines, with expected quarterly earnings of $0.14 per share and revenues projected at $85.54 million, representing an 8.4% year-over-year increase.
- Stable Earnings Expectations: Although the consensus EPS estimate has remained unchanged over the past 30 days, the rising interest in Tactile Systems Technology indicates investor confidence in its future profitability.
- Industry Ranking Stability: Tactile Systems Technology currently holds a Zacks Rank of 3 (Hold), similar to its peer Avanos Medical, which also saw a slight increase in share price, indicating overall stability in the medical device sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TCMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TCMD
Wall Street analysts forecast TCMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.650
Low
28.00
Averages
31.67
High
35.00
Current: 30.650
Low
28.00
Averages
31.67
High
35.00
About TCMD
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tactile Systems Technology Shares Rise 8.1% on Strong Volume
- Strong Price Performance: Tactile Systems Technology's shares rose 8.1% in the last trading session, closing at $30.28 with significantly higher-than-average trading volume, reflecting market optimism about its future performance.
- Business Growth Momentum: The company continues to show growth in its lymphedema and airway clearance business lines, with expected quarterly earnings of $0.14 per share and revenues projected at $85.54 million, representing an 8.4% year-over-year increase.
- Stable Earnings Expectations: Although the consensus EPS estimate has remained unchanged over the past 30 days, the rising interest in Tactile Systems Technology indicates investor confidence in its future profitability.
- Industry Ranking Stability: Tactile Systems Technology currently holds a Zacks Rank of 3 (Hold), similar to its peer Avanos Medical, which also saw a slight increase in share price, indicating overall stability in the medical device sector.
See More
Tactile Systems Technology Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $75.3 million in Q1 2026, reflecting a 23% year-over-year increase, indicating strong market performance and sustained customer demand.
- Margin Improvement: Gross margins rose to 76.5%, up 250 basis points from 74% in Q1 2025, showcasing the company's successful strategies in cost control and product pricing.
- Upgraded Full-Year Guidance: The company raised its full-year revenue guidance for 2026 to a range of $360 million to $368 million, projecting a year-over-year growth of approximately 9% to 12%, demonstrating increased management confidence in future performance.
- FDA Approval for New Product: The company received FDA 510(k) clearance for its next-generation AffloVest product, which is expected to further drive sales growth and enhance competitive positioning in the market.
See More
Tactile Systems (TCMD) Q1 2026 Earnings Transcript
See More
Tactile Systems Reports Strong Earnings, Stock Surges 18%
- Impressive Earnings: Tactile Systems Technology's Q4 and full-year 2025 earnings report revealed a 21% revenue increase to $103.6 million and a 9% rise in net income to $10.6 million ($0.46 per share), surpassing analyst expectations and demonstrating strong market performance.
- Sales Growth: The company attributed part of its revenue increase to a 66% surge in airway clearance product sales, alongside a 16% rise in sales and rentals of lymphedema treatment devices, indicating robust demand in specific medical sectors.
- Optimistic Guidance: Management forecasts an 8% to 11% revenue growth for 2026, projecting revenues between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, reflecting confidence in future growth.
- Significant Market Potential: As the population ages and medical technology advances, the medical device market is poised for continued growth, with Tactile Systems excelling in multiple niches, suggesting further market share expansion opportunities ahead.
See More
Tactile Systems Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $103.6 million in Q4 2025, reflecting a robust 21% increase that surpassed analyst expectations of $94 million, indicating strong performance in the medical device market.
- Profitability Improvement: The company's net income under GAAP rose by 9% to $10.6 million ($0.46 per share), showcasing sustained profitability and further bolstering investor confidence in the company's financial health.
- Strong Product Sales: Sales of airway clearance products surged by 66%, while sales and rentals of lymphedema treatment devices increased by 16%, demonstrating the effectiveness of the company's targeted strategies in niche markets.
- Optimistic Outlook: Management anticipates revenue growth of 8% to 11% in 2026, projecting figures between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, highlighting the company's growth potential and market confidence moving forward.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Tactile Systems Technology Shares Rise 8.1% on Strong Volume
- Strong Price Performance: Tactile Systems Technology's shares rose 8.1% in the last trading session, closing at $30.28 with significantly higher-than-average trading volume, reflecting market optimism about its future performance.
- Business Growth Momentum: The company continues to show growth in its lymphedema and airway clearance business lines, with expected quarterly earnings of $0.14 per share and revenues projected at $85.54 million, representing an 8.4% year-over-year increase.
- Stable Earnings Expectations: Although the consensus EPS estimate has remained unchanged over the past 30 days, the rising interest in Tactile Systems Technology indicates investor confidence in its future profitability.
- Industry Ranking Stability: Tactile Systems Technology currently holds a Zacks Rank of 3 (Hold), similar to its peer Avanos Medical, which also saw a slight increase in share price, indicating overall stability in the medical device sector.
See More
Tactile Systems Technology Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $75.3 million in Q1 2026, reflecting a 23% year-over-year increase, indicating strong market performance and sustained customer demand.
- Margin Improvement: Gross margins rose to 76.5%, up 250 basis points from 74% in Q1 2025, showcasing the company's successful strategies in cost control and product pricing.
- Upgraded Full-Year Guidance: The company raised its full-year revenue guidance for 2026 to a range of $360 million to $368 million, projecting a year-over-year growth of approximately 9% to 12%, demonstrating increased management confidence in future performance.
- FDA Approval for New Product: The company received FDA 510(k) clearance for its next-generation AffloVest product, which is expected to further drive sales growth and enhance competitive positioning in the market.
See More
Tactile Systems (TCMD) Q1 2026 Earnings Transcript
See More
Tactile Systems Reports Strong Earnings, Stock Surges 18%
- Impressive Earnings: Tactile Systems Technology's Q4 and full-year 2025 earnings report revealed a 21% revenue increase to $103.6 million and a 9% rise in net income to $10.6 million ($0.46 per share), surpassing analyst expectations and demonstrating strong market performance.
- Sales Growth: The company attributed part of its revenue increase to a 66% surge in airway clearance product sales, alongside a 16% rise in sales and rentals of lymphedema treatment devices, indicating robust demand in specific medical sectors.
- Optimistic Guidance: Management forecasts an 8% to 11% revenue growth for 2026, projecting revenues between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, reflecting confidence in future growth.
- Significant Market Potential: As the population ages and medical technology advances, the medical device market is poised for continued growth, with Tactile Systems excelling in multiple niches, suggesting further market share expansion opportunities ahead.
See More
Tactile Systems Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $103.6 million in Q4 2025, reflecting a robust 21% increase that surpassed analyst expectations of $94 million, indicating strong performance in the medical device market.
- Profitability Improvement: The company's net income under GAAP rose by 9% to $10.6 million ($0.46 per share), showcasing sustained profitability and further bolstering investor confidence in the company's financial health.
- Strong Product Sales: Sales of airway clearance products surged by 66%, while sales and rentals of lymphedema treatment devices increased by 16%, demonstrating the effectiveness of the company's targeted strategies in niche markets.
- Optimistic Outlook: Management anticipates revenue growth of 8% to 11% in 2026, projecting figures between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, highlighting the company's growth potential and market confidence moving forward.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
